Skip to content
All Podcasts – Lifestyle
Author:
KAZIA THERAPEUTICS LIMITED.
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
September 22, 2026
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
September 9, 2026
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
September 1, 2026
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
September 1, 2026
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
June 2, 2026
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
May 26, 2026
Aya Gold & Silver Reports High-Grade Exploration Drill Results at Boumadine
May 22, 2026
Aya Gold & Silver Reports Q1-2026 Results with Record Revenue and Cash Flow
May 21, 2026
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
April 15, 2026
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
April 13, 2026